Prospective observational study of functional decline and disabilities in the elderly living with lung cancer.

Conditions

Non-small cell lung cancer

Notsu M, Naito T, Mori K, Notsu A, Morikawa A, Kawabata T, Okayama T, Yonenaga Y, Sugiyama M, Kenmotsu H, Murakami H, Ito T, Kai M, Takahashi T.

2021-03-12

10.4103/2347-5625.311131

Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer.

Okayama T, Naito T, Yonenaga Y, Ohashi T, Kitagawa M, Mitsuhashi N, Ishi T, Fuseya H, Aoyama T, Notsu A, Mori K, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Tanuma A, Takahashi T.

2021-01-035 citations

10.1007/s00520-020-05953-5

Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.

Naito T, Okayama T, Aoyama T, Ohashi T, Masuda Y, Kimura M, Shiozaki H, Murakami H, Kenmotsu H, Taira T, Ono A, Wakuda K, Imai H, Oyakawa T, Ishii T, Omori S, Nakashima K, Endo M, Omae K, Mori K, Yamamoto N, Tanuma A, Takahashi T.

2017-11-2844 citations

10.1186/s12885-017-3795-2

Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.

Naito T, Okayama T, Aoyama T, Ohashi T, Masuda Y, Kimura M, Shiozaki H, Murakami H, Kenmotsu H, Taira T, Ono A, Wakuda K, Imai H, Oyakawa T, Ishii T, Omori S, Nakashima K, Endo M, Omae K, Mori K, Yamamoto N, Tanuma A, Takahashi T.

2017-08-2555 citations

10.1186/s12885-017-3562-4

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 0) Groups group 1: Patients receiving chemotherapy (n=30) group 2: Patients receiving radiotherapy (n=30) 1) >=70 years old 2) Non-small cell lung cancer in stage III , IV, or post-operative relapse. 3) They planned to receive the first anti-cancer treatment including radiotherapy, chemotherapy, or chemoradiotherapy. 4) ECOG-PS 0-2 5) Having written informed consent 6) They can be done physical assessment safely. 7) More than 12 weeks of survival was expected.

Exclusion criteria

Exclusion criteria: 1) They can not be done a physical assessment. 2) Having symptomatic brain metastasis.

Design outcomes

Primary

Measure	Time frame
The proportion of patients with physical functional decline or disabilities after 4 to 8 weeks after initiating chemotherapy.	—

Secondary

Measure	Time frame
The proportion of patients with physical functional decline or disabilities after 12 and 24 weeks after initiating chemotherapy.	—

Countries

Japan

Contacts

Public ContactTateaki Naito

Shizuoka Cancer Center Division of thoracic oncology

t.naito@scchr.jp055-989-5222

Outcome results